Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms (Q34565455)

3 August 2017

title

Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms (English)

1 reference

3 August 2017

0 references

Shiwei Deng

1

1 reference

3 August 2017

Tiandong Yan

2

1 reference

3 August 2017

Cathleen Jendrny

3

1 reference

3 August 2017

Andrea Nemecek

4

1 reference

3 August 2017

Mladen Vincetic

5

1 reference

3 August 2017

Ute Gödtel-Armbrust

6

1 reference

3 August 2017

Leszek Wojnowski

7

1 reference

3 August 2017

language of work or name

English

0 references

publication date

18 November 2014

1 reference

3 August 2017

1 reference

3 August 2017

volume

14

1 reference

3 August 2017

page(s)

842

1 reference

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

The evolution of gene expression levels in mammalian organs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Cardioprotective interventions for cancer patients receiving anthracyclines

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Topoisomerase levels determine chemotherapy responsein vitroandin vivo

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Cardioprotective interventions for cancer patients receiving anthracyclines

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Distinct roles of Topoisomerase II isoforms: DNA damage accelerating alpha, double strand break repair promoting beta

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Chronic health conditions in adult survivors of childhood cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Cardioprotective interventions for cancer patients receiving anthracyclines

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

The SUMO pathway is required for selective degradation of DNA topoisomerase IIbeta induced by a catalytic inhibitor ICRF-193(1)

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

DNA topoisomerase IIalpha and -beta expression in human ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Differential expression of the topoisomerase II alpha and beta genes in human breast cancers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4242484

The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity

7 July 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-14-842

The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-14-842

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-14-842

Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-14-842

Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-14-842

Anthracyclines, HER2, and TOP2A: the verdict

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-14-842

Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha

21 January 2018

1 reference

12 December 2020

N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance

1 reference

12 December 2020

The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues

1 reference

12 December 2020

Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines

1 reference

12 December 2020

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease

1 reference

12 December 2020

Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane

1 reference

12 December 2020

Should anthracyclines and dexrazoxane be used for children with cancer?

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-14-842

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference